{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T09:55:48Z","timestamp":1772531748486,"version":"3.50.1"},"reference-count":48,"publisher":"National Institute for Health and Care Research","issue":"47","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["11\/67\/01"],"award-info":[{"award-number":["11\/67\/01"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"\n Background<\/jats:title>\n Venous access devices are used for patients receiving long-term chemotherapy. These include centrally inserted tunnelled catheters or Hickman-type devices (Hickman), peripherally inserted central catheters (PICCs) and centrally inserted totally implantable venous access devices (PORTs).<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To evaluate the clinical effectiveness, safety, cost-effectiveness and acceptability of these devices for the central delivery of chemotherapy.<\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n An open, multicentre, randomised controlled trial to inform three comparisons: (1) peripherally inserted central catheters versus Hickman, (2) PORTs versus Hickman and (3) PORTs versus peripherally inserted central catheters. Pre-trial and post-trial qualitative research and economic evaluation were also conducted.<\/jats:p>\n <\/jats:sec>\n \n Setting<\/jats:title>\n This took place in 18 UK oncology centres.<\/jats:p>\n <\/jats:sec>\n \n Participants<\/jats:title>\n Adult patients (aged \u2265\u200918 years) receiving chemotherapy (\u2265\u200912 weeks) for either a solid or a haematological malignancy were randomised via minimisation.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Hickman, peripherally inserted central catheters and PORTs.<\/jats:p>\n <\/jats:sec>\n \n Primary outcome<\/jats:title>\n A composite of infection (laboratory confirmed, suspected catheter related and exit site infection), mechanical failure, venous thrombosis, pulmonary embolism, inability to aspirate blood and other complications in the intention-to-treat population.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Overall, 1061 participants were recruited to inform three comparisons. First, for the comparison of peripherally inserted central catheters (n<\/jats:italic>\u2009=\u2009212) with Hickman (n<\/jats:italic>\u2009=\u2009212), it could not be concluded that peripherally inserted central catheters were significantly non-inferior to Hickman in terms of complication rate (odds ratio 1.15, 95% confidence interval 0.78 to 1.71). The use of peripherally inserted central catheters compared with Hickman was associated with a substantially lower cost (\u2013\u00a31553) and a small decrement in quality-adjusted life-years gained (\u20130.009). Second, for the comparison of PORTs (n<\/jats:italic>\u2009=\u2009253) with Hickman (n<\/jats:italic>\u2009=\u2009303), PORTs were found to be statistically significantly superior to Hickman in terms of complication rate (odds ratio 0.54, 95% confidence interval 0.37 to 0.77). PORTs were found to dominate Hickman with lower costs (\u2013\u00a345) and greater quality-adjusted life-years gained (0.004). This was alongside a lower complications rate (difference of 14%); the incremental cost per complication averted was \u00a31.36. Third, for the comparison of PORTs (n<\/jats:italic>\u2009=\u2009147) with peripherally inserted central catheters (n<\/jats:italic>\u2009=\u2009199), PORTs were found to be statistically significantly superior to peripherally inserted central catheters in terms of complication rate (odds ratio 0.52, 95% confidence interval 0.33 to 0.83). PORTs were associated with an incremental cost of \u00a32706 when compared with peripherally inserted central catheters and a decrement in quality-adjusted life-years gained (\u20130.018) PORTs are dominated by peripherally inserted central catheters: alongside a lower complications rate (difference of 15%), the incremental cost per complication averted was \u00a3104. The qualitative work showed that attitudes towards all three devices were positive, with patients viewing their central venous access device as part of their treatment and recovery. PORTs were perceived to offer unique psychological benefits, including a greater sense of freedom and less intrusion in the context of personal relationships. The main limitation was the lack of adequate power (54%) in the non-inferiority comparison between peripherally inserted central catheters and Hickman.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n In the delivery of long-term chemotherapy, peripherally inserted central catheters should be considered a cost-effective option when compared with Hickman. There were significant clinical benefits when comparing PORTs with Hickman and with peripherally inserted central catheters. The health economic benefits were less clear from the perspective of incremental cost per quality-adjusted life-years gained. However, dependent on the willingness to pay, PORTs may be considered to be cost-effective from the perspective of complications averted.<\/jats:p>\n <\/jats:sec>\n \n Future work<\/jats:title>\n The deliverability of a PORTs service merits further study to understand the barriers to and methods of improving the service.<\/jats:p>\n <\/jats:sec>\n \n Trial registration<\/jats:title>\n This trial is registered as ISRCTN44504648.<\/jats:p>\n <\/jats:sec>\n \n Funding<\/jats:title>\n This project was funded by the National Institute for Health Research (NHIR) Health Technology Assessment programme and will be published in full in Health Technology Assessment<\/jats:italic>; Vol. 25, No. 47. See the NIHR Journals Library website for further project information.<\/jats:p>\n <\/jats:sec>","DOI":"10.3310\/hta25470","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T10:20:27Z","timestamp":1627467627000},"page":"1-126","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":23,"title":["Venous access devices for the delivery of long-term chemotherapy: the CAVA three-arm RCT"],"prefix":"10.3310","volume":"25","clinical-trial-number":[{"clinical-trial-number":"isrctn44504648","registry":"10.18810\/isrctn","type":"results"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0570-6016","authenticated-orcid":true,"given":"Olivia","family":"Wu","sequence":"first","affiliation":[{"name":"Health Economics and Health Technology Assessment (HEHTA), Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0260-4161","authenticated-orcid":true,"given":"Elaine","family":"McCartney","sequence":"additional","affiliation":[{"name":"Cancer Research UK Glasgow Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7396-4773","authenticated-orcid":true,"given":"Robert","family":"Heggie","sequence":"additional","affiliation":[{"name":"Health Economics and Health Technology Assessment (HEHTA), Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5576-8816","authenticated-orcid":true,"given":"Evi","family":"Germeni","sequence":"additional","affiliation":[{"name":"Health Economics and Health Technology Assessment (HEHTA), Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7367-5816","authenticated-orcid":true,"given":"James","family":"Paul","sequence":"additional","affiliation":[{"name":"Cancer Research UK Glasgow Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9022-9295","authenticated-orcid":true,"given":"Eileen","family":"Soulis","sequence":"additional","affiliation":[{"name":"Cancer Research UK Glasgow Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6676-1393","authenticated-orcid":true,"given":"Susan","family":"Dillon","sequence":"additional","affiliation":[{"name":"Cancer Research UK Glasgow Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7279-563X","authenticated-orcid":true,"given":"Caoimhe","family":"Ryan","sequence":"additional","affiliation":[{"name":"School of Social Sciences, University of Dundee, Dundee, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1294-356X","authenticated-orcid":true,"given":"Moira","family":"Sim","sequence":"additional","affiliation":[{"name":"Health Economics and Health Technology Assessment (HEHTA), Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5596-4400","authenticated-orcid":true,"given":"Judith","family":"Dixon-Hughes","sequence":"additional","affiliation":[{"name":"Cancer Research UK Glasgow Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3626-2008","authenticated-orcid":true,"given":"Roshan","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Oncology, Northampton General Hospital, Northampton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4726-4527","authenticated-orcid":true,"given":"Andrew","family":"Bodenham","sequence":"additional","affiliation":[{"name":"Intensive Care, Leeds Teaching Hospitals, Leeds, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3289-2344","authenticated-orcid":true,"given":"Tobias","family":"Menne","sequence":"additional","affiliation":[{"name":"Haematology, Newcastle Freeman Hospital, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9439-2353","authenticated-orcid":true,"given":"Brian","family":"Jones","sequence":"additional","affiliation":[{"name":"Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4589-9174","authenticated-orcid":true,"given":"Jonathan","family":"Moss","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6221","published-online":{"date-parts":[[2021,7]]},"reference":[{"key":"key20210727104202363_ref1-bib1","volume-title":"Cancer Reports","author":"National Cancer Registration and Analysis Service"},{"key":"key20210727104202363_ref1-bib2","volume-title":"Funding and Awards: Research Award","author":"National Institute for Health Research"},{"key":"key20210727104202363_ref1-bib3","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/bjc.2016.76","article-title":"Hickman catheter and implantable port devices for the delivery of chemotherapy: a phase II randomised controlled trial and economic evaluation","volume":"114","author":"Wu","year":"2016","journal-title":"Br J Cancer"},{"key":"key20210727104202363_ref1-bib4","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1007\/s00270-013-0771-3","article-title":"Centrally inserted external catheters and totally implantable ports for the delivery of chemotherapy: a systematic review and meta-analysis of device-related complications","volume":"37","author":"Kulkarni","year":"2014","journal-title":"Cardiovasc Intervent Radiol"},{"key":"key20210727104202363_ref1-bib5","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/NCC.0000000000000742","article-title":"Complications and costs of peripherally inserted central venous catheters compared with implantable port catheters for cancer patients: a meta-analysis","volume":"43","author":"Pu","year":"2020","journal-title":"Cancer Nurs"},{"key":"key20210727104202363_ref1-bib6","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1053\/jhin.2000.0886","article-title":"The epic project: developing national evidence-based guidelines for preventing healthcare associated infections: foreword","volume":"47","author":"Pratt","year":"2001","journal-title":"J Hosp Infect"},{"key":"key20210727104202363_ref1-bib7","volume-title":"Healthcare-associated Infections: Prevention and Control in Primary and Community Care","author":"National Institute for Health and Care Excellence (NICE)"},{"key":"key20210727104202363_ref1-bib8","volume-title":"Protocol 13PRT\/7956: Cancer And Venous Access (CAVA): A Randomised Controlled Trial with Associated Qualitative Research of Venous Access Devices for the Delivery of Long-term Chemotherapy (ISCRTN No 44504648).","author":"Moss"},{"key":"key20210727104202363_ref1-bib9","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","article-title":"Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on indirect treatment comparisons good research practices: part 2","volume":"14","author":"Hoaglin","year":"2011","journal-title":"Value Health"},{"key":"key20210727104202363_ref1-bib10","doi-asserted-by":"crossref","DOI":"10.1002\/9780470316696","volume-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin","year":"1987"},{"key":"key20210727104202363_ref1-bib11","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1002\/1097-0258(20001015)19:19<2657::AID-SIM557>3.0.CO;2-3","article-title":"Analysis of messy longitudinal data from a randomized clinical trial. MRC Lung Cancer Working Party","volume":"19","author":"Qian","year":"2000","journal-title":"Stat Med"},{"key":"key20210727104202363_ref1-bib12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"key20210727104202363_ref1-bib13","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s10985-010-9158-9","article-title":"Regression analysis of multivariate recurrent event data with a dependent terminal event","volume":"16","author":"Zhu","year":"2010","journal-title":"Lifetime Data Anal"},{"key":"key20210727104202363_ref1-bib14","volume-title":"Unit Costs of Health and Social Care 2019","author":"Curtis","year":"2019"},{"key":"key20210727104202363_ref1-bib15","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.12968\/bjon.2013.22.Sup19.S9","article-title":"Nurse-led PICC insertion: is it cost effective?","volume":"22","author":"Walker","year":"2013","journal-title":"Br J Nurs"},{"key":"key20210727104202363_ref1-bib16","unstructured":"NHS Improvement. Reference Costs 2017\u20132018: Highlights, Analysis and Introduction to the Data. London: Department of Health and Social Care; 2018."},{"key":"key20210727104202363_ref1-bib17","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/aas.13505","article-title":"Cost analysis comparison between peripherally inserted central catheters and implanted chest ports in patients with cancer \u2013 a health economic evaluation of the PICCPORT trial","volume":"64","author":"Taxbro","year":"2020","journal-title":"Acta Anaesthesiol Scand"},{"key":"key20210727104202363_ref1-bib18","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1111\/j.1365-2044.2004.03906.x","article-title":"Ultrasound for central venous cannulation: economic evaluation of cost-effectiveness","volume":"59","author":"Calvert","year":"2004","journal-title":"Anaesthesia"},{"key":"key20210727104202363_ref1-bib19","volume-title":"Data and Intelligence. Acute Medical: Specialty Costs","author":"Public Health Scotland"},{"key":"key20210727104202363_ref1-bib20","unstructured":"National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology Appraisal 2013. London: NICE; 2013."},{"key":"key20210727104202363_ref1-bib21","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"key":"key20210727104202363_ref1-bib22","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/hec.944","article-title":"Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility","volume":"14","author":"Manca","year":"2005","journal-title":"Health Econ"},{"key":"key20210727104202363_ref1-bib23","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1524-4733.2005.00045.x","article-title":"Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report","volume":"8","author":"Ramsey","year":"2005","journal-title":"Value Health"},{"key":"key20210727104202363_ref1-bib24","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s40273-014-0193-3","article-title":"A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials","volume":"32","author":"Faria","year":"2014","journal-title":"PharmacoEconomics"},{"key":"key20210727104202363_ref1-bib25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"Braun","year":"2006","journal-title":"Qual Res Psychol"},{"key":"key20210727104202363_ref1-bib26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1471-2288-6-34","article-title":"Increasing recruitment to randomised trials: a review of randomised controlled trials","volume":"6","author":"Watson","year":"2006","journal-title":"BMC Med Res Methodol"},{"key":"key20210727104202363_ref1-bib27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1745-6215-7-9","article-title":"What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies","volume":"7","author":"McDonald","year":"2006","journal-title":"Trials"},{"key":"key20210727104202363_ref1-bib28","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1136\/bmj.325.7367.766","article-title":"Quality improvement report: improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be difficult","volume":"325","author":"Donovan","year":"2002","journal-title":"BMJ"},{"key":"key20210727104202363_ref1-bib29","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1007\/s00405-013-2349-8","article-title":"The recruitment of patients to trials in head and neck cancer: a qualitative study of the EaStER trial of treatments for early laryngeal cancer","volume":"270","author":"Hamilton","year":"2013","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"key20210727104202363_ref1-bib30","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/1745-6215-12-78","article-title":"Key issues in recruitment to randomised controlled trials with very different interventions: a qualitative investigation of recruitment to the SPARE trial (CRUK\/07\/011)","volume":"12","author":"Paramasivan","year":"2011","journal-title":"Trials"},{"key":"key20210727104202363_ref1-bib31","doi-asserted-by":"publisher","first-page":"407","DOI":"10.5301\/jva.5000447","article-title":"Exploring attitudes towards a randomised controlled trial of venous access devices \u2013 a nested pre-trial qualitative study","volume":"16","author":"Ritchie","year":"2015","journal-title":"J Vasc Access"},{"key":"key20210727104202363_ref1-bib32","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0140-6736(13)60592-9","article-title":"Risk of venous thromboembolism associated with peripherally inserted central catheters: a systematic review and meta-analysis","volume":"382","author":"Chopra","year":"2013","journal-title":"Lancet"},{"key":"key20210727104202363_ref1-bib33","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1054\/clnu.2000.0103","article-title":"Complications and cost associated with parenteral nutrition delivered to hospitalized patients through either subclavian or peripherally-inserted central catheters","volume":"19","author":"Cowl","year":"2000","journal-title":"Clin Nutr"},{"key":"key20210727104202363_ref1-bib34","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.7326\/M15-0744","article-title":"The Michigan Appropriateness Guide for Intravenous Catheters (MAGIC): results from a multispecialty panel using the RAND\/UCLA appropriateness method","volume":"163","author":"Chopra","year":"2015","journal-title":"Ann Intern Med"},{"key":"key20210727104202363_ref1-bib35","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1200\/JCO.2012.45.5733","article-title":"Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline","volume":"31","author":"Schiffer","year":"2013","journal-title":"J Clin Oncol"},{"key":"key20210727104202363_ref1-bib36","doi-asserted-by":"publisher","first-page":"v152","DOI":"10.1093\/annonc\/mdv296","article-title":"Central venous access in oncology: ESMO Clinical Practice Guidelines","volume":"26","author":"Sousa","year":"2015","journal-title":"Ann Oncol"},{"key":"key20210727104202363_ref1-bib37","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/anae.13360","article-title":"Association of Anaesthetists of Great Britain and Ireland: safe vascular access 2016","volume":"71","author":"Bodenham","year":"2016","journal-title":"Anaesthesia"},{"key":"key20210727104202363_ref1-bib38","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.bja.2019.01.038","article-title":"Clinical impact of peripherally inserted central catheters vs. implanted port catheters in patients with cancer: an open-label, randomised, two-centre trial","volume":"122","author":"Taxbro","year":"2019","journal-title":"Br J Anaesth"},{"key":"key20210727104202363_ref1-bib39","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejca.2019.11.022","article-title":"Randomised phase II trial evaluating the safety of peripherally inserted catheters versus implanted port catheters during adjuvant chemotherapy in patients with early breast cancer","volume":"126","author":"Clatot","year":"2020","journal-title":"Eur J Cancer"},{"key":"key20210727104202363_ref1-bib40","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.clon.2007.04.003","article-title":"A comparison of Hickman line- and Port-a-Cath-associated complications in patients with solid tumours undergoing chemotherapy","volume":"19","author":"Ng","year":"2007","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"key20210727104202363_ref1-bib41","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00520-013-1941-1","article-title":"Comparison of peripherally inserted central venous catheters (PICC) versus subcutaneously implanted port-chamber catheters by complication and cost for patients receiving chemotherapy for non-haematological malignancies","volume":"22","author":"Patel","year":"2014","journal-title":"Support Care Cancer"},{"key":"key20210727104202363_ref1-bib42","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.jvs.2015.04.443","article-title":"Exploring patient involvement in decision making for vascular procedures","volume":"62","author":"Corriere","year":"2015","journal-title":"J Vasc Surg"},{"key":"key20210727104202363_ref1-bib43","doi-asserted-by":"publisher","first-page":"e026077","DOI":"10.1136\/bmjopen-2018-026077","article-title":"Patient acceptability of three different central venous access devices for the delivery of systemic anticancer therapy: a qualitative study","volume":"9","author":"Ryan","year":"2019","journal-title":"BMJ Open"},{"key":"key20210727104202363_ref1-bib44","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.12968\/bjon.2016.25.8.S4","article-title":"Proactive PICC placement: evaluating the patient experience","volume":"25","author":"Harrold","year":"2016","journal-title":"Br J Nurs"},{"key":"key20210727104202363_ref1-bib45","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejso.2006.08.003","article-title":"Patients\u2019 attitudes to totally implantable venous access port systems for gynecological or breast malignancies","volume":"33","author":"Kreis","year":"2007","journal-title":"Eur J Surg Oncol"},{"key":"key20210727104202363_ref1-bib46","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00520-017-3815-4","article-title":"Living with a peripherally inserted central catheter: the perspective of cancer outpatients-a qualitative study","volume":"26","author":"Par\u00e1s-Bravo","year":"2018","journal-title":"Support Care Cancer"},{"key":"key20210727104202363_ref1-bib47","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5172\/conu.2014.48.1.26","article-title":"The patient experience of a peripherally inserted central catheter (PICC): a qualitative descriptive study","volume":"48","author":"Sharp","year":"2014","journal-title":"Contemp Nurse"},{"key":"key20210727104202363_ref1-bib48","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1177\/1084822314566300","article-title":"Feeling confident in using PICC lines: patients experiences of living with a PICC line during chemotherapy treatment","volume":"27","author":"Alpenberg","year":"2015","journal-title":"Home Health Care Manag Pract"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2037196","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta25470\/hta25470.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2037196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T15:38:19Z","timestamp":1692113899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta25470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":48,"journal-issue":{"issue":"47","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["10.3310\/hta25470"],"URL":"https:\/\/doi.org\/10.3310\/hta25470","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"3-2013","name":"contractual_start_date","label":"Contractual start date","group":{"name":"article_history","label":"Article History"}},{"value":"4-2020","name":"editorial_review_begun","label":"Editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"12-2020","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}